Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study

Introduction The inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac, Sinovac) has been widely used in a two-dose schedule. We assessed whether a third dose of the homologous or a different vaccine could boost immune responses. <strong...

Полное описание

Библиографические подробности
Главные авторы:	Costa Clemens, SA, Weckx, L, Clemens, R, Almeida Mendes, AV, Ramos Souza, A, Silveira, MBV, da Guarda, SNF, de Nobrega, MM, de Moraes Pinto, MI, Gonzalez, IGS, Salvador, N, Franco, MM, de Avila Mendonça, RN, Queiroz Oliveira, IS, de Freitas Souza, BS, Fraga, M, Aley, P, Bibi, S, Cantrell, L, Dejnirattisai, W, Liu, X, Mongkolsapaya, J, Supasa, P, Screaton, GR, Lambe, T, Voysey, M, Pollard, AJ
Другие авторы:	RHH-001 study team
Формат:	Journal article
Язык:	English
Опубликовано:	Elsevier 2022

Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study

Схожие документы